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Abstract: The first synthesis of a naturally occurring tetrapeptide cyclo-(isoleucyl-prolyl-
leucyl-alanyl) has been achieved using a solution-phase technique via coupling of dipeptide 
segments  Boc-L-Pro-L-Leu-OH  and  L-Ala-L-Ile-OMe.  Deprotection  of  the  linear 
tetrapeptide unit and its subsequent cyclization gave a cyclopeptide, identical in all aspects 
to  the  naturally  occurring  compound.  Bioactivity  results  indicated  the  antifungal  and 
antihelmintic  potential  of  the  synthesized  peptide  against  pathogenic  dermatophytes 
and earthworms. 
Keywords:  natural  product  synthesis;  marine  bacteria;  cyclic  tetrapeptide;  biological 
activity; Halisarca ectofibrosa; Diginea sp. 
 
1. Introduction  
Naturally  occurring  cyclic  peptides  have  generated  much  interest  in  recent  years  due  to  their 
intriguing  chemical  structures  and  potent  biological  activity. They show therapeutic potential as a 
result of greater resistance to in vivo enzymatic degradation as well as greater bioavailability than 
non-cyclic analogs. Cyclooligopeptides, especially medium ring-sized peptides bearing aliphatic amino 
acid units, have been reported from diverse marine sources, including marine microorganisms [1–5]. 
These  cyclic  congeners  derived  from  marine  microorganisms  exhibit  a  range  of  pharmacological 
activities, including antimicrobial activity [6], cytotoxicity [7,8], anti-dinoflagellate activity [9] and 
inhibitory activity against enzyme sortase B [10]. A natural cyclotetrapeptide cyclo-(isoleucyl-prolyl-
leucyl-alanyl) has been isolated from the marine bacteria Pseudomonas sp. and Pseudoalteromonas sp., 
OPEN ACCESS Mar. Drugs 2011, 9  
 
 
72 
associated  with  the  seaweed  Diginea  sp.  and  the  sponge  Halisarca  ectofibrosa  and  the  peptide’s 
structure was elucidated on basis of LC-MS/2D NMR data [11]. 
Keeping in view the wide array of bioactivities possessed by natural cyclooligopeptides [12,13] and 
in continuation of our previous investigations on peptides [14–22], an attempt was made toward the 
synthesis of a natural cyclic tetrapeptide (4) employing a solution-phase synthesis method. In addition, 
the synthesized product was further subjected to anthelmintic and antimicrobial activity studies. 
2. Results and Discussion  
The title compound 4 was synthesized by the method shown in Scheme 1. In order to carry out the 
synthesis  of  cyclo-(isoleucyl-prolyl-leucyl-alanyl),  the  molecule  was  split  into  two  dipeptide  units: 
Boc-L-Pro-L-Leu-OMe  (1)  and  Boc-L-Ala-L-Ile-OMe  (2).  The  dipeptides  were  prepared  
by  coupling  Boc-amino  acids  viz.  Boc-L-Pro-OH  and  Boc-L-Ala-OH  with  respective  amino  
acid  methyl  ester  hydrochlorides  like  L-Leu-OMe.HCl  and  L-Ile-OMe.HCl  using  
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide  hydrochloride  (EDC.HCl)  as  coupling  agent  and 
pyridine as base [23]. The ester group of dipeptide 1 was removed with lithium hydroxide (LiOH) and 
deprotected  peptide  1a  was  coupled  with  dipeptide  2a  deprotected  at  the  amino  terminal  using 
trifluoroacetic acid (TFA), to get the linear tetrapeptide unit Boc-L-Pro-L-Leu-L-Ala-L-Ile-OMe (3). 
Finally, cyclization of the linear tetrapeptide 3 was done by the pentafluorophenyl ester method to 
obtain the cyclooligopeptide cyclo-(isoleucyl-prolyl-leucyl-alanyl) (4). Structures of newly synthesized 
cyclopeptide and intermediate peptides were elucidated by spectral/elemental analysis (Tables 1 and 2). 
Scheme 1. Synthesis of cyclotetrapeptide 4. 
+
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Scheme 1. Cont. 
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Table 1. Physical characterization data for 1–4. 
Compound 
Physical 
state 
M.p. 
(° C) 
α[D] 
a  
(° ) 
Yield 
(%) 
Rf 
b 
Mol. 
Formula 
(Mr) 
Elemental analysis 
Calcd./found (%) 
C  H  N 
1 
Viscous 
mass 
-  +71.4 
1  87  0.69 
C17H30N2O5  59.63  8.83  8.18 
(342)  59.62  8.85  8.21 
1a 
White 
solid 
79–80  +41.6  72  0.53 
C16H28N2O5  58.52  8.59  8.53 
(328)  58.49  8.62  8.55 
2 
Viscous 
mass 
-  −121.8  93  0.87 
C15H28N2O5  56.94  8.92  8.85 
(316)  56.95  8.94  8.83 
2a 
Semisolid 
mass 
-  −89.2  78  0.66 
C10H20N2O3  55.53  9.32  12.95 
(216)  55.52  9.35  12.97 
3 
Semisolid 
mass 
-  −55.1 
2  91  0.81 
C26H46N4O7  59.29  8.80  10.64 
(526)  59.26  8.79  10.66 
4 
White 
solid 
198 (d) 
−12.9 
3 
(−13.0) 
74  0.62 * 
C20H34N4O4  60.89  8.69  14.20 
(394)  60.91  8.70  14.18 
a c, 0.5 in MeOH; 
1 c, 0.25 in MeOH; 
2 c, 0.15 in MeOH; 
3 c, 0.05 in MeOH; 
b (CHCl3:MeOH/7:3); 
* (CHCl3:MeOH/9:1). 
Table 2. Spectral data for 1–4. 
Compound  IR (CHCl3/KBr, v cm
−1), 
1H/
13C NMR (CDCl3, δ ppm), ESIMS/MS (rel. int., m/z) 
1 
3128, 3123 (NH str, amide), 2998–2989 (CH str, CH2, Pro), 2966, 2928 (CH str, 
asym,  CH3  and  CH2),  1748  (C=O  str,  ester),  1675,  1643  (C=O  str,  tert  and 
sec amide), 1539 (N–H def, sec amide), 1391, 1377 (C–H def, tert-Butyl), 1384, 1369 
(C–H def, iso-propyl), 1267 (C–O str, ester) 
6.65 (1H, br. s, NH), 4.40 (1H, q, H-, Leu), 4.05 (1H, t, J = 7.2 Hz, H-, Pro), 3.62 
(3H, s, OCH3), 3.22 (2H, t, J = 7.2 Hz, H-, Pro), 2.58 (2H, q, H-, Pro), 1.96–1.88 
(2H, m, H-, Pro), 1.47 (9H, s, tert-Butyl), 1.45–1.36 (3H, m, H- and H-, Leu), 0.94 
(6H, d, J = 6.35 Hz, H-, Leu)  Mar. Drugs 2011, 9  
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1a 
3297–2478 (m/br, OH str, COOH), 3125, 3122 (NH str, amide), 2999–2992 (CH str, 
CH2, Pro), 2968, 2929 (CH str, asym, CH3 and CH2), 1711 (s, C=O str, COOH), 1678, 
1642 (C=O str,  tert and sec amide), 1536 (N–H def, sec amide), 1393, 1375 (C–H def, 
tert-Butyl), 1385, 1368 (C–H def, iso-propyl) 
12.52 (1H, s, OH, COOH), 6.73 (1H, br. s, NH), 4.47 (1H, q, H-, Leu), 3.86 (1H, t, 
J = 7.2 Hz,  H-,  Pro),  3.21  (2H,  t,  J  =  7.15  Hz,  H-,  Pro),  2.55  (2H,  q,  H-,  Pro),  
1.95–1.87 (3H, m, H-, Pro and Leu), 1.56 (2H, t, H-, Leu), 1.49 (9H, s, tert-Butyl), 
0.95 (6H, d, J = 6.4 Hz, H-, Leu) 
2 
3502, 3396 (NH str, sec amine), 3132, 3127 (NH str, amide), 2965, 2928 (CH str, 
asym, CH3 and CH2), 2874 (CH str, sym, CH3), 1747 (C=O str, ester), 1646 (C=O str,   
sec amide), 1535 (N–H def, sec amide), 1269 (C–O str, ester), 1159 (C–N str, sec amine) 
5.89 (1H, br. s, NH), 4.28 (1H, t, J = 6.4 Hz, H-, Ile), 3.75–3.69 (1H, m, H-, Ala), 
3.51 (3H, s, OCH3), 2.03–1.95 (1H, m, H-, Ile), 1.70–1.62 (2H, m, H-, Ile), 1.46 (2H, br. 
s, NH2), 1.15 (3H, d, J = 7.25 Hz, H-, Ala), 0.94 (3H, t, J = 7.2 Hz, H-, Ile), 0.86 (3H, d, 
J = 6.4 Hz, H-′, Ile) 
3 
3129–3122 (NH str, amide), 2999–2993 (CH str, CH2, Pro), 2968, 2929, 2925 (CH str, 
asym,  CH3  and CH2), 2878–2873  (CH  str,  sym,  CH3), 1745 (C=O str, ester), 1676,   
1646–1641 (C=O str, tert and sec amide), 1538, 1535 (N–H def, sec amide), 1392, 1375 
(C–H def, tert-Butyl), 1386, 1368 (C–H def, iso-propyl), 1272 (C–O str, ester) 
8.48 (1H, br. s, NH), 7.45 (1H, br. s, NH), 5.14 (1H, br. s, NH), 4.52 (1H, q, H-, Leu), 
4.25 (1H, q, H-, Ala), 4.14 (1H, t, J = 7.2 Hz, H-, Pro), 3.73 (1H, t, J = 6.35 Hz, H-, 
Ile), 3.49 (3H, s, OCH3), 3.43 (2H, t,  J = 7.25 Hz, H-, Pro), 2.49 (2H, q, H-, Pro),  
2.05–1.97 (1H, m, H-, Ile), 1.95–1.89 (2H, m, H-, Pro), 1.83–1.62 (4H, m, H-, Leu and 
H-, Ile), 1.48 (9H, s, tert-Butyl), 1.48–1.43 (1H, m, H-, Leu), 1.29 (3H, d, J = 7.2 Hz, 
H-, Ala), 0.99 (6H, d, J = 6.4 Hz, H-, Leu), 0.93 (3H, t, J = 7.15 Hz, H-, Ile), 0.89 (3H, 
d, J = 6.45 Hz, H-′, Ile) 
174.8 (C=O, Leu), 172.9, 172.4 (2C, C=O, Pro and Ile), 169.8 (C=O, Ala), 156.2 (C=O, Boc), 
79.8 (C-, tert-Butyl), 59.7 (C-, Pro), 58.5 (C-, Ile), 54.7 (OCH3), 51.3 (C-, Ala), 
49.7 (C-, Leu), 46.9 (C-, Pro), 37.6, 37.1 (2C, C-, Ile and Leu), 28.9 (C-, Pro), 28.2 
(3C, C-, tert-Butyl), 24.2, 23.9 (2C, C-, Ile and Leu), 23.7 (C-, Pro), 22.3 (2C, C-, Leu), 
17.9 (C-, Ala), 15.1 (C-′, Ile), 9.5 (C-, Ile) 
4 
3128,  3123,  3119  (NH  str,  amide),  2998,  2995–2992  (CH  str,  CH2,  Pro),  2969,   
2928–2924  (CH  str,  asym,  CH3  and CH2), 2879, 2875 (C H  str,  sym,  CH3), 1675,  
1648–1643 (C=O str, tert and sec amide), 1539–1536 (N–H def, sec amide), 1385, 1369 
(C–H def, iso-propyl) 
9.37 (1H, br. s, NH), 9.31 (1H, br. s, NH), 7.76 (1H, br. s, NH), 4.26 (1H, t, J = 7.15 Hz, 
H-, Pro), 3.99 (1H, q, H-, Ala), 3.95 (1H, q, H-, Leu), 3.61 (1H, t, J = 6.4 Hz, H-, 
Ile), 3.52 (2H, t, J = 7.3 Hz, H-, Pro), 2.35 (2H, q, H-, Pro), 1.96–1.83 (2H, m, H-, Pro), 
1.89–1.83 (1H, m, H-, Leu), 1.81–1.76 (1H, m, H-, Ile), 1.73–1.64 (2H, m, H-, Leu), 
1.59–1.53 (2H, m, H-, Ile), 1.45 (3H, d, J = 7.25 Hz, H-, Ala), 0.98 (6H, d, J = 6.35 Hz, 
H-, Leu), 0.95 (3H, d, J = 6.45 Hz, H-′, Ile), 0.89 (3H, t, J = 7.2 Hz, H-, Ile) 
171.1 (C=O, Leu), 170.9 (C=O, Ala), 170.5, 168.1 (2C, C=O, Pro and Ile), 63.3 (C-, Ile), 
57.5 (C-, Pro), 54.1 (C-, Leu), 49.9 (C-, Ala), 46.5 (C-, Pro), 43.8, 39.9 (2C, C-, Leu 
and Ile), 29.9 (C-, Pro), 24.8, 24.2 (2C, C-, Ile and Leu), 22.0 (2C, C-, Leu), 21.3 (C-, 
Pro), 19.2 (C-, Ala), 15.4 (C-′, Ile), 9.8 (C-, Ile) Mar. Drugs 2011, 9  
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Table 2. Cont. 
4 
395.4  [(M  +  H)
+,  100],  367.4  [(395.4  −  CO)
+,  11],  324.4  [(H -Ile-Pro-Leu)
+,  32], 
298.4 [(H-Leu-Ala-Ile)
+,  39],  296.4  [(324.4  −  CO)
+, 10], 282.3 [(H -Ala-Ile-Pro)
+, 29], 
270.3  [(298.4  −  CO)
+,  17],  254.3  [(282.3  −  CO)
+,  15],  211.3  [(H -Ile-Pro)
+,  19], 
185.2 [(H-Leu-Ala)
+, 76], 157.2 [(185.2 − CO)
+, 12], 114.1 [(H-Leu)
+, 19], 86.1 [Ile/Leu 
(C5H12N)
+, 16], 70.1 [Pro (C 4H8N)
+, 10], 57.1 [(C 4H9)
+, 15], 44.1 [Ala (C2H6N)
+, 12], 
43.1 [(C3H7)
+, 11], 29.1 [(C2H5)
+, 9], 15.0 [(CH3)
+, 13] 
Synthesis of the natural cyclotetrapeptide 4 was completed successfully from the linear precursor 
and N-methylmorpholine (NMM) was proven to be an effective base for cyclizing linear tetrapeptide 
segment. Disappearance of absorption bands at 1745, 1272 cm
−1 and 1392, 1375 cm
−1 (C=Ostr and  
C–Ostr, methyl ester group and C–Hbend, tert-Butyl group) in FT-IR spectrum of 4 clearly indicated 
cyclization of the linear tetrapeptide unit. This fact was further supported by the disappearance in the 
1H NMR spectrum of 4 of two singlets at δ 1.48 and δ 3.49 corresponding to protons of tert-Butyl and 
methyl ester groups of 3. Four signals between δ 4.26–3.61 in the proton spectrum of 4 suggested a 
peptidic structure for the synthesized product, with these signals being attributable to the α-protons of 
all amino acid units. The 
1H NMR spectrum of the cyclized product showed the presence of three 
broad singlets between δ 9.37–7.76 corresponding to the imino protons of the isoleucine, leucine and 
alanine moieties, the remaining amino acid being the proline unit, indicating similarity of the structure 
of the newly synthesized cyclotetrapeptide with the natural molecule. The NMR data of the synthetic 
cyclotetrapeptide are identical with those of the natural product within the error range of δ 0.06 (
1H) 
and  1  (
13C),  respectively.  Moreover, 
1H/
13C  NMR  spectra  of  the  cyclized  product  4  showed 
characteristic peaks confirming the presence of all the 34 protons and 20 carbon atoms. Presence of 
pseudomolecular ion peak at m/z 395.4 corresponding to the molecular formula C20H34N4O4 in the 
mass  spectrum  of  4,  along  with  other  fragment  ion  peaks  resulting  from  cleavage  at  “Leu-Pro”, 
“Ile-Ala” and “Ala-Leu” amide bonds, showed the exact sequence of attachment of all the four amino 
acid units in the chain. In addition, elemental data analysis of 4 afforded values (± 0.02) strictly in 
accordance with the molecular composition.  
The newly synthesized cyclooligopeptide 4 exhibited potent anthelmintic activity at a concentration 
of 2 mg/mL in tween 80 (0.5%) and distilled water. Comparison of the anthelmintic activity data 
revealed that the cyclopeptide 4 displayed greater activity than it’s corresponding linear precursor 3 and 
the standard drug, mebendazole, against all three earthworm species M. konkanensis, P. corethruses 
and E. eugeniea (Table 3).  
Analysis of the antimicrobial activity data indicated that cyclopeptide 4, compared to the standard 
drug  gatifloxacin,  displayed  moderate  antibacterial  activity  against  the  Gram-negative  bacteria  
P.  aeruginosa  and  K.  pneumoniae,  and  antifungal  activity  against  pathogenic  C.  albicans  with 
minimum inhibitory concentration (MIC) values of 6 g/mL. Moreover, 4 displayed potent bioactivity 
against dermatophytes M. audouinii and T. mentagrophytes with MIC values of 6 μg/mL. However, 
4 displayed  no  bioactivity  against  either  Gram-positive  bacteria  or  against  the  fungus  A.  niger 
(Table 4). Mar. Drugs 2011, 9  
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Table 3. Anthelmintic screening data for 3 and 4. 
Compound 
Earthworm species 
M. konk.  P. core.  E. euge. 
Mean 
paralyzing 
time (min) 
‡ 
Mean  
death  
time (min) 
‡ 
Mean 
paralyzing 
time (min) 
Mean  
death  
time (min) 
Mean 
paralyzing 
time (min) 
Mean  
death  
time (min) 
3 
† 
4 
† 
Control 
# 
Mebendazole 
† 
14.25 ±  0.42  
9.28 ±  0.20 
- 
13.85 ±  0.64 
22.57 ±  0.36 
18.27 ±  0.17 
- 
22.85 ±  0.53 
18.11 ±  0.26 
12.44 ±  0.19 
- 
17.82 ±  0.43 
29.47 ±  0.14 
23.55 ±  0.27 
- 
29.60 ±  0.22 
14.12 ±  0.23 
12.40 ±  0.13 
- 
13.54 ±  0.45 
24.54 ±  0.12 
22.05 ±  0.37 
- 
24.05 ±  0.62 
M. konk.: Megascoplex konkanensis; P. core.: Pontoscotex corethruses; E. euge.: Eudrilus eugeniea;  
† Conc. = 2 mg/mL; 
‡ Data are given as mean ±  S.D. (n = 3); 
# Tween 80 (0.5%) in distilled water. 
Table 4. Antimicrobial screening data for 3 and 4. 
Compound 
Diameter of zone of inhibition (mm) 
Bacterial strains  Fungal strains 
B. sub.  S. aur.  P. aeru.  K. pneu.  C. alb.  M. audo.  A. niger  T. menta. 
3  -  -  13(6) 
†  16(6)  12(6)  18(6)  -  19(6) 
4  -  -  18(6)  20(6)  15(6)  23(6)  -  25(6) 
Control *  -  -  -  -  -  -  -  - 
Gatifloxacin  18(12.5)  28(6)  22(6)  25(6)  -  -  -  - 
Griseofulvin  -  -  -  -  20(6)  17(6)  18(12.5)  20(6) 
B.  sub.:  Bacillus  subtilis;  S.  aur.:  Staphylococcus  aureus;  P.  aeru.:  Pseudomonas  aeruginosa;  
K. pneu.: Klebsiella pneumoniae; C. alb.: Candida albicans; M. audo.: Microsporum audouinii;  
A. niger: Aspergillus niger; T. menta.: Trichophyton mentagrophytes;  
† Values in bracket are MIC values (g/mL); * DMF/DMSO. 
3. Experimental Section 
Melting points were determined in open capillaries and are uncorrected. IR spectra were recorded on 
a Shimadzu 8700 FTIR spectrophotometer and 
1H/
13C NMR spectra were recorded on a Bruker AC 
NMR spectrometer (300 MHz) using deuterated chloroform as solvent and TMS as internal standard. 
The  mass  spectra  were  recorded  on  a  JMS-DX  303  Mass  spectrometer  operating  at  70  eV  by 
ESIMS/MS.  Optical  rotation  of  synthesized  peptide  derivatives  was  measured  on  an  automatic 
polarimeter at 25 ° C using a sodium lamp. Elemental analysis of all compounds was performed on a 
Vario  EL  III  elemental  analyzer.  Purity  of  all  synthesized  compounds  was  checked  by  TLC  on 
precoated silica gel G plates. 
3.1. Extraction and Isolation of Natural Cyclic Tetrapeptide 
As reported earlier, a bacterial strain identified as a Pseudomonas sp. by 16S rRNA analysis was 
obtained from the Japanese seaweed Diginea sp., an alga which has a symbiotic relationship with 
dinoflagellates such as Amphidinium sp. The colonies inhibited the growth of other marine bacteria 
when  grown  on  seawater  based  agar  medium.  Purification  by  SiO2  column  chromatography  and 
reversed-phase  HPLC  of  the  CHCl3-MeOH  soluble  fractions  of  the  culture  supernatant  gave Mar. Drugs 2011, 9  
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peptide-containing  fractions  that  were  analyzed  by 
1H  NMR  and  by  LC-MS.  Extensive  2D  NMR 
analysis of the individual cyclopeptide components confirmed the isolation of the novel cyclotetrapeptide 
cyclo-(isoleucyl-prolyl-leucyl-alanyl) in addition to other previously characterized peptides [11].  
The culture broth (1.5 L) of a bacterial strain No. 27 (Pseudomonas sp.) was centrifuged, and the 
bacterial  cells  were  extracted  with  CHCl3/MeOH  (1:1,  500  mL).  The  combined  extracts  were 
concentrated,  and  the  residue  was  partitioned  with  EtOAc  and  water.  The  EtOAc  layer  (152 mg) 
showed potent antimicrobial activity against an orange-colored unidentified bacterium associated with 
the same host (Diginea sp.). After further separation by Si gel chromatography and elution using a 
solvent  gradient  of  hexanes/CHCl3/EtOAc/MeOH,  the  fraction  eluted  in  EtOAc/MeOH  (1:1)  was 
subjected to  reverse  phase HPLC  using a MeOH/H2O gradient  from 50 to  100% MeOH and UV 
detection at 215 nm to give the desired cyclic tetrapeptide (2.0 mg).  
3.2. General Procedure for the Preparation of Linear Dipeptide Fragments 
L-Amino acid methyl ester hydrochloride (0.01 mol) was dissolved in CH2Cl2 (20 mL). Pyridine 
(1.61 mL, 0.021 mol) was added to the mixture at 0 C and stirred for 15 min. Boc-L-amino acid  
(0.01 mol) was dissolved in CH2Cl2 (20 mL) followed by addition of EDC.HCl (1.92 g, 0.01 mol) and 
HOBt (1.34 g, 0.01 mol). The resulting mixture was added to the above solution with constant shaking 
and stirring was continued for 24 h. The reaction mixture was filtered and the residue was washed with 
CH2Cl2 (30 mL) and added to the filtrate. The filtrate was washed with 5% NaHCO3 and saturated 
NaCl  solutions.  The  organic  layer  was  dried  over  anhydrous  Na2SO4,  filtered  and  evaporated  
in vacuum. The crude product was recrystallized from a mixture of chloroform and petroleum ether  
(b.p. 40–60 C) followed by cooling at 0 C to get the title compounds.  
3.3. Procedure for the Synthesis of Linear Tetrapeptide Unit and Its Cyclization 
L-Alanyl-L-isoleucine  methyl  ester  2a  (2.16  g,  0.01  mol)  was  dissolved  in  DMF  (25  mL)  and 
pyridine (0.021 mol) was added to the above solution in proportions. Finally, the reaction mixture was 
stirred for 30 minutes, while maintaining the temperature between 05 C. Boc-L-prolyl-L-leucine 1a 
(3.28 g, 0.01 mol) was dissolved in DMF (35 mL) and EDC.HCl (1.92 g, 0.01 mol) and HOBt (1.34 g, 
0.01 mol) were added in proportions while stirring. Stirring was first done for 1 h at 05 C and then 
further for 24 h at room temperature (RT). After the completion of the reaction, the reaction mixture 
was diluted with an equal amount of water. The precipitated solid was filtered, washed with water and 
recrystallized from a mixture of chloroform and petroleum ether (b.p. 4060 C), followed by cooling 
at 0 C to get Boc-L-prolyl-L-leucyl-L-alanyl-L-isoleucine methyl ester 3. The linear tetrapeptide unit 3 
(2.63 g, 0.005 mol) was deprotected at the carboxyl terminal using lithium hydroxide (LiOH, 0.18 g, 
0.0075 mol) to obtain Boc-L-prolyl-L-leucyl-L-alanyl-L-isoleucine-OH. To a solution of the deprotected 
tetrapeptide  (2.56  g,  0.005  mol)  in  CHCl3  (50  mL),  pentafluorophenol  (1.23 g,  0.0067  mol)  and 
EDC.HCl (0.96 g, 0.005 mol) were added followed by stirring at RT for 12 h. Filtrate of the above 
reaction mixture was washed with 10% NaHCO3 (3 ×  20 mL) and 5% HCl (2 ×  20 mL) solutions to 
obtain  corresponding  pentafluorophenyl  ester  Boc-L-prolyl-L-leucyl-L-alanyl-L-isoleucine-Opfp. 
Boc-group of resulting unit (2.71 g, 0.004 mol) was removed using TFA (0.91 g, 0.008 mol) and 
deprotected product was dissolved in CHCl3 (25 mL) and TEA/NMM/pyridine (2.8 mL or 2.21 mL or Mar. Drugs 2011, 9  
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1.61 mL, 0.021 mol) was added. Whole contents were then kept at 0 °C  for 7 days. The reaction 
mixture was washed with 10% NaHCO3 (3 ×  25 mL) and 5% HCl (2 ×  25 mL) solutions. The organic 
layer  was  dried  over  anhydrous  Na2SO4 and the crude cyclized compound was recrystallized from 
CHCl3/n-hexane to obtain the pure cyclic product 4. 
3.4. Biological Activity Studies 
3.4.1. Antihelmintic Screening 
Newly synthesized linear and cyclic tetrapeptide 3 and 4 were subjected to antihelmintic activity 
studies against three different species of earthworms Megascoplex konkanensis, Pontoscotex corethruses 
and Eudrilus eugeniea at a concentration of 2 mg/mL using Garg’s method [24]. Tween 80 (0.5%) in 
distilled water was used as control and mebendazole was used as a standard drug. Suspensions of 
samples  were prepared by triturating synthesized compounds (100 mg) with tween 80 (0.5%) and 
distilled water and the resulting mixtures  were stirred using a mechanical  stirrer for 30 min. The 
suspensions were diluted to contain 0.2% (w/v) of the test samples. Suspension of the reference drug, 
mebendazole,  was  prepared  with  the  same  concentration  in  a  similar  way.  Three  sets  of  five 
earthworms of almost similar sizes (2 inches in length) were placed in petri plates of 4 inch diameter 
containing  50  mL  of  suspension  of  test  sample  and  reference  drug  at  RT.  Another  set  of  five 
earthworms was kept as control in 50 mL suspension of distilled water and tween 80 (0.5%). The 
paralyzing and death times were noted and their mean was calculated for triplicate sets. The death time 
was ascertained by placing the earthworms in warm water (50 C), which stimulated the movement if 
the worm was alive. The results of antihelmintic screening are tabulated in Table 3. 
3.4.2. Antimicrobial Screening 
Antibacterial and antifungal screening of synthesized tetrapeptides 3 and 4 were carried out against 
the Gram-positive bacteria Bacillus subtilis and Staphylococcus aureus, the Gram-negative bacteria 
Pseudomonas  aeruginosa  and  Klebsiella  pneumoniae,  dermatophytes  Microsporum  audouinii  and 
Trichophyton  mentagrophytes,  as  well  as  Candida  albicans  and  other  fungal  strains,  including 
Aspergillus niger at a concentration of 12.56 g/mL. A modified Kirby-Bauer disc diffusion method 
was used for testing [25]. MIC values of test compounds were determined by tube dilution technique. 
Newly synthesized tetrapeptides were dissolved separately to prepare a stock solution of 1 mg/mL 
using DMF. Stock solution was aseptically transferred and suitably diluted with sterile broth medium 
to  contain  seven  different  concentrations  of  each  test  compound  ranging  from  200–3.1  μg/mL  in 
different test tubes. All the tubes were inoculated with one loopful of one of the test bacteria/fungi. The 
process was repeated with different test bacteria/fungi and different samples. Tubes inoculated with 
bacterial/fungal  cultures  were  incubated  at  37  C  for  18  h  and  48  h,  respectively,  and  the 
presence/absence of growth of the bacteria/fungi was observed. From these results, MIC of each test 
compound was determined against each test bacterium/fungus. A spore suspension in sterile distilled 
water  was  prepared  from  5  days  old  culture  of  the  test  bacteria/fungi  growing  on  nutrient  broth 
media/sabouraud’s broth media. About 20 mL of the growth medium was transferred into sterilized 
petri  plates  and  inoculated  with  1.5  mL  of  the  spore  suspension  (spore  concentration: Mar. Drugs 2011, 9  
 
 
79 
6  10
4 spores/mL).  Filter  paper  disks  of  6  mm  diameter  and  1  mm  thickness  were  sterilized  by 
autoclaving at 121 C (15 psig) for 15 min. Each petri plate was divided into five equal portions along 
the diameter to place one disc. Three discs of test sample were placed on three portions together with 
one disc with reference drug and a disk impregnated with the solvent as negative control. The petri 
plates inoculated with bacterial cultures were incubated at 37 C for 18 h and those inoculated with 
fungal cultures were incubated at 37 C for 48 h. Gatifloxacin and griseofulvin were used as reference 
drugs  and DMF/DMSO were used as control. Diameters of the zones of inhibition (in mm) were 
measured and the average diameters for test sample were calculated for triplicate sets. The diameters 
obtained for the test sample were compared with that produced by the standard drugs. The results of 
antibacterial and antifungal studies are presented in Table 4. 
4. Conclusions  
First total synthesis of the naturally occurring tetrapeptide cyclo-(isoleucyl-prolyl-leucyl-alanyl) 4 
was  accomplished  with  good  yield  via  coupling  reactions  utilizing  carbodiimide  chemistry. 
Pentafluorophenyl ester was proven to be effective for the activation of the acid functionality of the 
linear tetrapeptide unit. NMM was found to be a good base for intramolecular cyclization of the linear 
peptide fragment in comparison to TEA and pyridine. Synthesized cyclotetrapeptide 4 displayed potent 
antihelmintic activity against earthworms M. konkanensis, P. corethruses and E. eugeniea, along with 
good antifungal activity against dermatophytes M. audouinii and T. mentagrophytes, compared to the 
reference drugs, mebendazole and griseofulvin. In comparison, Gram-negative bacteria were found to 
be  more  sensitive  than  Gram-positive  bacteria  toward  the  newly  synthesized  peptide.  On  passing 
toxicity tests, the newly synthesized cyclooligopeptide 4 may prove to be a good candidate for clinical 
studies and can in the future become an anthelmintic and antidermatophyte agent. 
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